Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

This study found that recovery from immunoparesis (IP) in newly diagnosed, transplant-ineligible multiple myeloma patients was associated with significantly longer progression-free survival (PFS) and overall survival (OS), making it a valuable prognostic factor. IP recovery also enhanced prognosis in patients who were minimal residual disease (MRD) negative, suggesting it complements MRD status as a predictor of outcomes.